388 related articles for article (PubMed ID: 16940204)
1. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
Jasmin JF; Mercier I; Dupuis J; Tanowitz HB; Lisanti MP
Circulation; 2006 Aug; 114(9):912-20. PubMed ID: 16940204
[TBL] [Abstract][Full Text] [Related]
2. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression.
Jasmin JF; Mercier I; Hnasko R; Cheung MW; Tanowitz HB; Dupuis J; Lisanti MP
Cardiovasc Res; 2004 Sep; 63(4):747-55. PubMed ID: 15306231
[TBL] [Abstract][Full Text] [Related]
3. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
4. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
[TBL] [Abstract][Full Text] [Related]
5. A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression.
Haga S; Tsuchiya H; Hirai T; Hamano T; Mimori A; Ishizaka Y
Exp Lung Res; 2015 Feb; 41(1):21-31. PubMed ID: 25275723
[TBL] [Abstract][Full Text] [Related]
6. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats.
Mathew R; Zeballos GA; Tun H; Gewitz MH
Cardiovasc Res; 1995 Nov; 30(5):739-46. PubMed ID: 8595621
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
[TBL] [Abstract][Full Text] [Related]
8. [Effects of various doses of monocrotaline administration on the development of pulmonary hypertension and its regression in rats].
Kakusaka I; Kaneko N; Kiyatake K; Fujita A; Suzuki A; Nakano K; Okada O; Sugita T; Watanabe S; Kuriyama T
Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Jan; 27(1):51-6. PubMed ID: 2501548
[TBL] [Abstract][Full Text] [Related]
9. Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension.
Mathew R; Huang J; Shah M; Patel K; Gewitz M; Sehgal PB
Circulation; 2004 Sep; 110(11):1499-506. PubMed ID: 15353500
[TBL] [Abstract][Full Text] [Related]
10. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
[TBL] [Abstract][Full Text] [Related]
11. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
12. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension.
Kanki-Horimoto S; Horimoto H; Mieno S; Kishida K; Watanabe F; Furuya E; Katsumata T
Circulation; 2006 Jul; 114(1 Suppl):I181-5. PubMed ID: 16820570
[TBL] [Abstract][Full Text] [Related]
13. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
14. Characterization of erectile function in monocrotaline-treated pulmonary hypertensive rats.
Gur S; Kadowitz PJ; Thammasitboon S; Lasky JA; Hellstrom WJ
J Androl; 2009; 30(5):495-504. PubMed ID: 19201699
[TBL] [Abstract][Full Text] [Related]
15. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
16. Monocrotaline induces interleukin-6 mRNA expression in rat lungs.
Bhargava A; Kumar A; Yuan N; Gewitz MH; Mathew R
Heart Dis; 1999; 1(3):126-32. PubMed ID: 11720614
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats.
Yip HK; Chang LT; Sun CK; Sheu JJ; Chiang CH; Youssef AA; Lee FY; Wu CJ; Fu M
Crit Care Med; 2008 Mar; 36(3):873-80. PubMed ID: 18431275
[TBL] [Abstract][Full Text] [Related]
18. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats.
Mitani Y; Maruyama K; Sakurai M
Circulation; 1997 Jul; 96(2):689-97. PubMed ID: 9244244
[TBL] [Abstract][Full Text] [Related]
19. [Preventive effects of tetrandrine on pulmonary hypertension and right ventricular hypertrophy in rats induced by monocrotaline].
Jin X; Zhang X; Xing J; Liu K; Wang H
Zhongguo Zhong Yao Za Zhi; 1996 Dec; 21(12):751-2, 763. PubMed ID: 9812685
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
